Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance

James M. Backes, Carmelo Venero, Cheryl A. Gibson, Janelle F. Ruisinger, Patricia A. Howard, Paul D. Thompson, Patrick M. Moriarty

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

BACKGROUND: Statins are generally well tolerated, but some patients discontinue therapy secondary to adverse effects. Dosing a statin (rosuvastatin) every other day (EOD) may provide significant lipoprotein changes white avoiding common adverse effects in this statin-intolerant population. OBJECTIVE: To determine the effect and tolerance of EOD rosuvastatin in patients previously intolerant to statin therapy. METHODS: We performed a retrospective analysis of patients treated with EOD rosuvastatin at 2 lipid specialty clinics: the University of Kansas Lipid, Atherosclerosis, and LDL-Apheresis Center and the Hartford Hospital Cholesterol Management Center. Approximately 2600 charts were reviewed to identify patients receiving rosuvastatin EOD who previously had experienced statin intolerance. Fifty-one patients were eligible for the analysis, which evaluated changes in the lipid profile, the number achieving their low-density lipoprotein cholesterol (LDL-C) goals, and the percent tolerating rosuvastatin EOD. Laboratory data were assessed immediately prior to rosuvastatin EOD therapy and at the first follow-up. RESULTS: Myalgias (76.5%) and increased transaminase levels (19.5%) were the most common causes of prior statin Intolerance, but 72.5% (37/51) of patients were able to tolerate the EOD therapy (mean dose 5.6 mg) regimen for 4 ± 2.9 (mean ± SD) months. Mean LDL-C decreased 34.5% (p < 0.001) in the patients who tolerated the regimen, enabling approximately 50% to achieve their LDL-C goal. All patierrts who were considered to be intolerant to rosuvastatin EOD therapy (27.5%; 14/51) reexperienced the symptoms of their prior statin intolerance. CONCLUSIONS: Treating patients intolerant to statins with rosuvastatin EOD was tolerated by the majority of patients and reduced LDL-C in our study. This dosing strategy may be useful in patients intolerant to once-daily statin dosing, although such an approach has not been documented to reduce cardiovascular events.

Original languageEnglish (US)
Pages (from-to)341-346
Number of pages6
JournalAnnals of Pharmacotherapy
Volume42
Issue number3
DOIs
StatePublished - Mar 1 2008

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Cholesterol
Lipids
Rosuvastatin Calcium
Therapeutics
Blood Component Removal
Myalgia
Transaminases
Lipoproteins
Atherosclerosis
Cholesterol

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Backes, J. M., Venero, C., Gibson, C. A., Ruisinger, J. F., Howard, P. A., Thompson, P. D., & Moriarty, P. M. (2008). Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Annals of Pharmacotherapy, 42(3), 341-346. https://doi.org/10.1345/aph.1K604

Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. / Backes, James M.; Venero, Carmelo; Gibson, Cheryl A.; Ruisinger, Janelle F.; Howard, Patricia A.; Thompson, Paul D.; Moriarty, Patrick M.

In: Annals of Pharmacotherapy, Vol. 42, No. 3, 01.03.2008, p. 341-346.

Research output: Contribution to journalArticle

Backes, JM, Venero, C, Gibson, CA, Ruisinger, JF, Howard, PA, Thompson, PD & Moriarty, PM 2008, 'Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance', Annals of Pharmacotherapy, vol. 42, no. 3, pp. 341-346. https://doi.org/10.1345/aph.1K604
Backes, James M. ; Venero, Carmelo ; Gibson, Cheryl A. ; Ruisinger, Janelle F. ; Howard, Patricia A. ; Thompson, Paul D. ; Moriarty, Patrick M. / Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. In: Annals of Pharmacotherapy. 2008 ; Vol. 42, No. 3. pp. 341-346.
@article{0e3adb8a391a4a9683c93f5db7d22104,
title = "Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance",
abstract = "BACKGROUND: Statins are generally well tolerated, but some patients discontinue therapy secondary to adverse effects. Dosing a statin (rosuvastatin) every other day (EOD) may provide significant lipoprotein changes white avoiding common adverse effects in this statin-intolerant population. OBJECTIVE: To determine the effect and tolerance of EOD rosuvastatin in patients previously intolerant to statin therapy. METHODS: We performed a retrospective analysis of patients treated with EOD rosuvastatin at 2 lipid specialty clinics: the University of Kansas Lipid, Atherosclerosis, and LDL-Apheresis Center and the Hartford Hospital Cholesterol Management Center. Approximately 2600 charts were reviewed to identify patients receiving rosuvastatin EOD who previously had experienced statin intolerance. Fifty-one patients were eligible for the analysis, which evaluated changes in the lipid profile, the number achieving their low-density lipoprotein cholesterol (LDL-C) goals, and the percent tolerating rosuvastatin EOD. Laboratory data were assessed immediately prior to rosuvastatin EOD therapy and at the first follow-up. RESULTS: Myalgias (76.5{\%}) and increased transaminase levels (19.5{\%}) were the most common causes of prior statin Intolerance, but 72.5{\%} (37/51) of patients were able to tolerate the EOD therapy (mean dose 5.6 mg) regimen for 4 ± 2.9 (mean ± SD) months. Mean LDL-C decreased 34.5{\%} (p < 0.001) in the patients who tolerated the regimen, enabling approximately 50{\%} to achieve their LDL-C goal. All patierrts who were considered to be intolerant to rosuvastatin EOD therapy (27.5{\%}; 14/51) reexperienced the symptoms of their prior statin intolerance. CONCLUSIONS: Treating patients intolerant to statins with rosuvastatin EOD was tolerated by the majority of patients and reduced LDL-C in our study. This dosing strategy may be useful in patients intolerant to once-daily statin dosing, although such an approach has not been documented to reduce cardiovascular events.",
author = "Backes, {James M.} and Carmelo Venero and Gibson, {Cheryl A.} and Ruisinger, {Janelle F.} and Howard, {Patricia A.} and Thompson, {Paul D.} and Moriarty, {Patrick M.}",
year = "2008",
month = "3",
day = "1",
doi = "10.1345/aph.1K604",
language = "English (US)",
volume = "42",
pages = "341--346",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "3",

}

TY - JOUR

T1 - Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance

AU - Backes, James M.

AU - Venero, Carmelo

AU - Gibson, Cheryl A.

AU - Ruisinger, Janelle F.

AU - Howard, Patricia A.

AU - Thompson, Paul D.

AU - Moriarty, Patrick M.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - BACKGROUND: Statins are generally well tolerated, but some patients discontinue therapy secondary to adverse effects. Dosing a statin (rosuvastatin) every other day (EOD) may provide significant lipoprotein changes white avoiding common adverse effects in this statin-intolerant population. OBJECTIVE: To determine the effect and tolerance of EOD rosuvastatin in patients previously intolerant to statin therapy. METHODS: We performed a retrospective analysis of patients treated with EOD rosuvastatin at 2 lipid specialty clinics: the University of Kansas Lipid, Atherosclerosis, and LDL-Apheresis Center and the Hartford Hospital Cholesterol Management Center. Approximately 2600 charts were reviewed to identify patients receiving rosuvastatin EOD who previously had experienced statin intolerance. Fifty-one patients were eligible for the analysis, which evaluated changes in the lipid profile, the number achieving their low-density lipoprotein cholesterol (LDL-C) goals, and the percent tolerating rosuvastatin EOD. Laboratory data were assessed immediately prior to rosuvastatin EOD therapy and at the first follow-up. RESULTS: Myalgias (76.5%) and increased transaminase levels (19.5%) were the most common causes of prior statin Intolerance, but 72.5% (37/51) of patients were able to tolerate the EOD therapy (mean dose 5.6 mg) regimen for 4 ± 2.9 (mean ± SD) months. Mean LDL-C decreased 34.5% (p < 0.001) in the patients who tolerated the regimen, enabling approximately 50% to achieve their LDL-C goal. All patierrts who were considered to be intolerant to rosuvastatin EOD therapy (27.5%; 14/51) reexperienced the symptoms of their prior statin intolerance. CONCLUSIONS: Treating patients intolerant to statins with rosuvastatin EOD was tolerated by the majority of patients and reduced LDL-C in our study. This dosing strategy may be useful in patients intolerant to once-daily statin dosing, although such an approach has not been documented to reduce cardiovascular events.

AB - BACKGROUND: Statins are generally well tolerated, but some patients discontinue therapy secondary to adverse effects. Dosing a statin (rosuvastatin) every other day (EOD) may provide significant lipoprotein changes white avoiding common adverse effects in this statin-intolerant population. OBJECTIVE: To determine the effect and tolerance of EOD rosuvastatin in patients previously intolerant to statin therapy. METHODS: We performed a retrospective analysis of patients treated with EOD rosuvastatin at 2 lipid specialty clinics: the University of Kansas Lipid, Atherosclerosis, and LDL-Apheresis Center and the Hartford Hospital Cholesterol Management Center. Approximately 2600 charts were reviewed to identify patients receiving rosuvastatin EOD who previously had experienced statin intolerance. Fifty-one patients were eligible for the analysis, which evaluated changes in the lipid profile, the number achieving their low-density lipoprotein cholesterol (LDL-C) goals, and the percent tolerating rosuvastatin EOD. Laboratory data were assessed immediately prior to rosuvastatin EOD therapy and at the first follow-up. RESULTS: Myalgias (76.5%) and increased transaminase levels (19.5%) were the most common causes of prior statin Intolerance, but 72.5% (37/51) of patients were able to tolerate the EOD therapy (mean dose 5.6 mg) regimen for 4 ± 2.9 (mean ± SD) months. Mean LDL-C decreased 34.5% (p < 0.001) in the patients who tolerated the regimen, enabling approximately 50% to achieve their LDL-C goal. All patierrts who were considered to be intolerant to rosuvastatin EOD therapy (27.5%; 14/51) reexperienced the symptoms of their prior statin intolerance. CONCLUSIONS: Treating patients intolerant to statins with rosuvastatin EOD was tolerated by the majority of patients and reduced LDL-C in our study. This dosing strategy may be useful in patients intolerant to once-daily statin dosing, although such an approach has not been documented to reduce cardiovascular events.

UR - http://www.scopus.com/inward/record.url?scp=41149180129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149180129&partnerID=8YFLogxK

U2 - 10.1345/aph.1K604

DO - 10.1345/aph.1K604

M3 - Article

VL - 42

SP - 341

EP - 346

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 3

ER -